359 related articles for article (PubMed ID: 24661664)
21. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
[TBL] [Abstract][Full Text] [Related]
22. Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
Steber CR; Hughes RT; Soike MH; Jacobson T; Helis CA; Farris JC; Farris MK
Clin Lung Cancer; 2021 Jan; 22(1):e122-e131. PubMed ID: 33046359
[TBL] [Abstract][Full Text] [Related]
23. Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT).
Reyngold M; Wu AJ; McLane A; Zhang Z; Hsu M; Stein NF; Zhou Y; Ho AY; Rosenzweig KE; Yorke ED; Rimner A
Radiat Oncol; 2013 Apr; 8():99. PubMed ID: 23617949
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Muller DA; Dutta SW; Aliotta E; Sanders JC; Wijesooriya K; Watkins WT; Larner JM
Clin Lung Cancer; 2021 May; 22(3):234-241. PubMed ID: 32690439
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.
Miyakawa A; Shibamoto Y; Baba F; Manabe Y; Murai T; Sugie C; Yanagi T; Takaoka T
Radiat Oncol; 2017 Sep; 12(1):152. PubMed ID: 28893300
[TBL] [Abstract][Full Text] [Related]
26. Re-Irradiation of Locoregional NSCLC Recurrence Using Robotic Stereotactic Body Radiotherapy.
Ceylan C; Hamacı A; Ayata H; Berberoglu K; Kılıç A; Güden M; Engin K
Oncol Res Treat; 2017; 40(4):207-214. PubMed ID: 28324876
[TBL] [Abstract][Full Text] [Related]
27. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
28. Thoracic Reirradiation with Stereotactic Body Radiation Therapy (SBRT) for Recurrent Advanced Non-Small Cell Lung Cancer (NSCLC).
Ross D; Chan D; Kuo E; Harkenrider M
Pract Radiat Oncol; 2024; 14(3):234-240. PubMed ID: 38387781
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
30. Thoracic reirradiation with SBRT for residual/recurrent and new primary NSCLC within or immediately adjacent to a prior high-dose radiation field.
Horne ZD; Dohopolski MJ; Clump DA; Burton SA; Heron DE
Pract Radiat Oncol; 2018; 8(3):e117-e123. PubMed ID: 29724402
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
[TBL] [Abstract][Full Text] [Related]
32. Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection.
Hayes JT; David EA; Qi L; Chen AM; Daly ME
Clin Lung Cancer; 2015 Sep; 16(5):379-84. PubMed ID: 25737143
[TBL] [Abstract][Full Text] [Related]
33. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236.
Stanic S; Paulus R; Timmerman RD; Michalski JM; Barriger RB; Bezjak A; Videtic GM; Bradley J
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1092-9. PubMed ID: 24661663
[TBL] [Abstract][Full Text] [Related]
34. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
35. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
Barriger RB; Forquer JA; Brabham JG; Andolino DL; Shapiro RH; Henderson MA; Johnstone PA; Fakiris AJ
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):457-62. PubMed ID: 21035956
[TBL] [Abstract][Full Text] [Related]
36. Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.
Liang X; Penagaricano J; Zheng D; Morrill S; Zhang X; Corry P; Griffin RJ; Han EY; Hardee M; Ratanatharathom V
Radiat Oncol; 2016 Jan; 11():10. PubMed ID: 26800883
[TBL] [Abstract][Full Text] [Related]
37. Radiomics for prediction of radiation-induced lung injury and oncologic outcome after robotic stereotactic body radiotherapy of lung cancer: results from two independent institutions.
Bousabarah K; Blanck O; Temming S; Wilhelm ML; Hoevels M; Baus WW; Ruess D; Visser-Vandewalle V; Ruge MI; Treuer H; Kocher M
Radiat Oncol; 2021 Apr; 16(1):74. PubMed ID: 33863358
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic body radiation therapy for post-pulmonary lobectomy isolated lung metastasis of thoracic tumor: survival and side effects.
Xiong W; Xu Q; Xu Y; Sun C; Li N; Zhou L; Liu Y; Zhou X; Wang Y; Wang J; Bai S; Lu Y; Gong Y
BMC Cancer; 2014 Sep; 14():719. PubMed ID: 25260301
[TBL] [Abstract][Full Text] [Related]
39. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
[TBL] [Abstract][Full Text] [Related]
40. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors.
Nguyen KNB; Hause DJ; Novak J; Monjazeb AM; Daly ME
Pract Radiat Oncol; 2019 Mar; 9(2):e196-e202. PubMed ID: 30496842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
